Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Common Equity (2016 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Common Equity for 14 consecutive years, with $6.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 118.1% year-over-year to $6.4 million, compared with a TTM value of $6.4 million through Dec 2025, up 118.1%, and an annual FY2025 reading of $7.1 million, up 760.39% over the prior year.
  • Common Equity was $6.4 million for Q4 2025 at Neuroone Medical Technologies, down from $7.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $15.9 million in Q4 2021 and bottomed at $822013.0 in Q3 2024.
  • Average Common Equity over 5 years is $6.9 million, with a median of $6.5 million recorded in 2021.
  • The sharpest move saw Common Equity soared 1032.53% in 2021, then crashed 86.85% in 2024.
  • Year by year, Common Equity stood at $15.9 million in 2021, then crashed by 48.76% to $8.2 million in 2022, then crashed by 45.93% to $4.4 million in 2023, then crashed by 33.56% to $2.9 million in 2024, then skyrocketed by 118.1% to $6.4 million in 2025.
  • Business Quant data shows Common Equity for NMTC at $6.4 million in Q4 2025, $7.1 million in Q3 2025, and $8.2 million in Q2 2025.